Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794923 · ClinicalTrials.gov registry record · Phase 3
Topical Ibuprofen for Delayed Onset Mulscle Soreness
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
NCT01794923 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 205 participants.
The verdict
NCT01794923, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
Study Summary
The objective of this study is to compare the efficacy and safety of Ibuprofen 5% Topical Gel versus placebo administered two or three times daily for the treatment of pain associated with delayed onset muscle soreness following intense eccentric exercise of the elbow flexor muscles.
Interventions
- DRUG Placebo BID
- DRUG Placebo TID
- DRUG IBU BID
- DRUG IBU TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2013-06-13 |
| Est. Completion | 2014-03-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794923
The ClinicalTrials.gov registry entry for NCT01794923 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo BID is the first listed.
NCT01794923 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01794923 about?
NCT01794923 is a clinical study titled "Topical Ibuprofen for Delayed Onset Mulscle Soreness". The objective of this study is to compare the efficacy and safety of Ibuprofen 5% Topical Gel versus placebo administered two or three times daily for the treatment of pain associated with delayed onset muscle soreness following intense eccentric exercise of the elbow flexor muscles.
What is the current status of trial NCT01794923?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2013-06-13. Estimated completion is 2014-03-29.
What interventions are being tested in trial NCT01794923?
The interventions under investigation include: Placebo BID (DRUG), Placebo TID (DRUG), IBU BID (DRUG), IBU TID (DRUG).
Who is sponsoring clinical trial NCT01794923?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.